| Literature DB >> 29431694 |
Iris Hecht1, Amir Toporik2, Joseph R Podojil3,4, Ilan Vaknin2, Gady Cojocaru2, Anat Oren2, Elizabeta Aizman2, Spencer C Liang5, Ling Leung5, Yosef Dicken2, Amit Novik2, Nadav Marbach-Bar2, Aziza Elmesmari6, Clare Tange6, Ashley Gilmour6, Donna McIntyre6, Mariola Kurowska-Stolarska6, Kay McNamee7, Judith Leitner8, Shirley Greenwald2, Liat Dassa2, Zurit Levine2, Peter Steinberger8, Richard O Williams7, Stephen D Miller3,4, Iain B McInnes6, Eyal Neria2, Galit Rotman2.
Abstract
The B7-like protein family members play critical immunomodulatory roles and constitute attractive targets for the development of novel therapies for human diseases. We identified Ig-like domain-containing receptor (ILDR)2 as a novel B7-like protein with robust T cell inhibitory activity, expressed in immune cells and in immune-privileged and inflamed tissues. A fusion protein, consisting of ILDR2 extracellular domain with an Fc fragment, that binds to a putative counterpart on activated T cells showed a beneficial effect in the collagen-induced arthritis model and abrogated the production of proinflammatory cytokines and chemokines in autologous synovial-like cocultures of macrophages and cytokine-stimulated T cells. Collectively, these findings point to ILDR2 as a novel negative regulator for T cells, with potential roles in the development of immune-related diseases, including autoimmunity and cancer.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29431694 PMCID: PMC6860365 DOI: 10.4049/jimmunol.1700325
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422